Related Experiment Videos
Imidazoline compounds protect against interleukin 1beta-induced beta-cell apoptosis
S V Zaitsev1, I B Appelskog, I L Kapelioukh
1Rolf Luft Center for Diabetes Research, Department of Molecular Medicine, Karolinska Institutet, Stockholm, Sweden. sergei.zaitsev@enk.ks.se
Diabetes
|March 29, 2001
Summary
Imidazoline compounds protect pancreatic beta-cells from interleukin-1beta-induced apoptosis by inhibiting inducible nitric oxide synthase (iNOS). This suggests potential therapeutic applications for type 1 and type 2 diabetes.
Area of Science:
- Endocrinology
- Molecular Biology
- Pharmacology
Background:
- Interleukin-1beta (IL-1beta) induces apoptosis in pancreatic beta-cells, contributing to diabetes.
- Imidazoline compounds are being explored for type 2 diabetes treatment.
Purpose of the Study:
- To investigate the protective effects of imidazoline compounds against IL-1beta-induced beta-cell apoptosis.
- To elucidate the signal transduction pathways involved in IL-1beta-induced beta-cell apoptosis.
Main Methods:
- Investigated the role of calcium (Ca2+) influx and calcineurin in beta-cell apoptosis.
- Assessed the involvement of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production.
- Utilized imidazoline compounds (RX871024, efaroxan) and pathway inhibitors (D-600, KT5823).
Main Results:
- IL-1beta-induced beta-cell apoptosis was suppressed by inhibiting Ca2+ influx and by calcineurin.
- Apoptosis correlated with iNOS expression and increased intracellular NO.
- Imidazoline compounds RX871024 and efaroxan protected beta-cells from apoptosis, likely via iNOS inhibition.
Conclusions:
- Imidazolines may protect pancreatic beta-cells by inhibiting iNOS, a key mediator of IL-1beta-induced apoptosis.
- These findings support the exploration of imidazoline compounds as therapeutic agents for type 1 and type 2 diabetes.